258 related articles for article (PubMed ID: 29288020)
1. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
Chen CH; Hung CH; Wang JH; Lu SN; Hu TH; Lee CM
Clin Microbiol Infect; 2018 Sep; 24(9):997-1003. PubMed ID: 29288020
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
[TBL] [Abstract][Full Text] [Related]
3. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
[TBL] [Abstract][Full Text] [Related]
4. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
Chen CH; Lu SN; Hung CH; Wang JH; Hu TH; Changchien CS; Lee CM
J Hepatol; 2014 Sep; 61(3):515-22. PubMed ID: 24798617
[TBL] [Abstract][Full Text] [Related]
5. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
[TBL] [Abstract][Full Text] [Related]
6. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
Chen CH; Hsu YC; Lu SN; Hung CH; Wang JH; Lee CM; Hu TH
J Viral Hepat; 2018 May; 25(5):590-597. PubMed ID: 29274189
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.
Yao CC; Hung CH; Hu TH; Lu SN; Wang JH; Lee CM; Chen CH
Sci Rep; 2017 May; 7(1):1839. PubMed ID: 28500322
[TBL] [Abstract][Full Text] [Related]
8. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
9. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
10. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.
Lin TC; Chiu YC; Chiu HC; Liu WC; Cheng PN; Chen CY; Chang TT; Wu IC
World J Gastroenterol; 2018 Feb; 24(6):725-736. PubMed ID: 29456411
[TBL] [Abstract][Full Text] [Related]
12. Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B.
Atay K; Hatemi İ; Canbakan B; Köroğlu E; Durcan E; Yurttaş B; Gültepe İ; Özdemir S; Tuncer M; Sonsuz A
Turk J Gastroenterol; 2016 May; 27(3):279-83. PubMed ID: 27210786
[TBL] [Abstract][Full Text] [Related]
13. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy.
Chen CH; Hung CH; Wang JH; Lu SN; Lai HC; Hu TH; Lin CH; Peng CY
J Infect Dis; 2019 Apr; 219(10):1624-1633. PubMed ID: 30689910
[TBL] [Abstract][Full Text] [Related]
14. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
15. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
16. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
17. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
18. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
[TBL] [Abstract][Full Text] [Related]
19. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
20. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridi M; Hadziyannis E; Berby F; Zachou K; Testoni B; Rigopoulou E; Gatselis NK; Lyberopoulou A; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Papatheodoridis GV
J Viral Hepat; 2020 Feb; 27(2):118-126. PubMed ID: 31562748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
